From the Open-Publishing Calendar
From the Open-Publishing Newswire
Indybay Feature
Study Confirms Long-term Cannabis Use Is Safe
A study of patients using medical cannabis to control chronic pain has confirmed that prolonged use is safe. Researchers found that pain patients using medical cannabis were no more likely to suffer serious adverse events than non-cannabis patients.
The “Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)” was published online last month in the Journal of Pain. COMPASS included chronic pain patients using medical cannabis and a control group that was not, all selected from seven Canadian pain clinics.
The principal investigator for the study was Mark Ware, M.D., Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre and Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids.
“This is the first and largest study of the long-term safety of medical cannabis use by patients suffering from chronic pain, ever conducted,” said Dr. Ware. “We found that medical cannabis, when used by patients who are experienced users and as part of a monitored treatment program for chronic pain over one year, appears to have a reasonable safety profile.”
“Dr. Ware’s research clinically documents how safe medical cannabis can be for pain management,” said ASA Executive Director Steph Sherer. “This study is an example of the type of research we can expect in America once federal barriers are removed.”
U.S. research is hampered by the classification of cannabis listed as a Schedule I drug, the most highly restricted category. The National Institutes of Drug Abuse is still the only source for research cannabis in the U.S. despite a ruling from a DEA Administrative Law Judge that more federal cultivation licenses should be issued.
More Information:
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
http://www.jpain.org/article/S1526-5900%2815%2900837-8/abstract?cc=y=
The principal investigator for the study was Mark Ware, M.D., Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre and Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids.
“This is the first and largest study of the long-term safety of medical cannabis use by patients suffering from chronic pain, ever conducted,” said Dr. Ware. “We found that medical cannabis, when used by patients who are experienced users and as part of a monitored treatment program for chronic pain over one year, appears to have a reasonable safety profile.”
“Dr. Ware’s research clinically documents how safe medical cannabis can be for pain management,” said ASA Executive Director Steph Sherer. “This study is an example of the type of research we can expect in America once federal barriers are removed.”
U.S. research is hampered by the classification of cannabis listed as a Schedule I drug, the most highly restricted category. The National Institutes of Drug Abuse is still the only source for research cannabis in the U.S. despite a ruling from a DEA Administrative Law Judge that more federal cultivation licenses should be issued.
More Information:
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
http://www.jpain.org/article/S1526-5900%2815%2900837-8/abstract?cc=y=
For more information:
http://www.safeaccessnow.org/asa_activist_...
Add Your Comments
We are 100% volunteer and depend on your participation to sustain our efforts!
Get Involved
If you'd like to help with maintaining or developing the website, contact us.
Publish
Publish your stories and upcoming events on Indybay.
Topics
More
Search Indybay's Archives
Advanced Search
►
▼
IMC Network